Verona Pharma plc (VRNA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Here's Why 'Trend' Investors Would Love Betting on Verona Pharma (VRNA)
Verona Pharma (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Wall Street Analysts See a 30.65% Upside in Verona Pharma (VRNA): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 30.7% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Verona Pharma (VRNA) Upgraded to Buy: What Does It Mean for the Stock?
Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Verona Pharma (VRNA) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited
Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's broad label and significant prescriber uptake suggest potential for higher-than-expected peak annual sales. Verona Pharma holds $336 million in cash, projecting operational funding through at least the end of 2026.
Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value
Verona Pharma has seen its share price skyrocket in anticipation of the commercial launch of its COPD treatment.
Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript
Verona Pharma plc (NASDAQ:VRNA ) Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Christopher Martin - Chief Commercial Officer Tara Rheault - Chief Development Officer Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler. Raghuram Selvaraju - HC Wainwright Tom Shrader - BTIG Edward Thomason - VLK Joon Lee - Truist Boobalan Pachaiyappan - Roth Capital Partners Operator Good morning, everyone, and welcome to Verona Pharma's Third Quarter 2024 Financial Results and Operating Highlights Conference Call.
Recent Price Trend in Verona Pharma (VRNA) is Your Friend, Here's Why
Verona Pharma (VRNA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts Think Verona Pharma (VRNA) Could Surge 25.25%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 25.3% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Verona Pharma (VRNA) Is a Great Choice for 'Trend' Investors, Here's Why
Verona Pharma (VRNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care
Verona Pharma's Ohtuvayre (ensifentrine) was approved for COPD in June 2024, introducing a novel dual mechanism of action. Ohtuvayre is priced at $2,950 per month, significantly above ICER's cost-effectiveness benchmark of $7,500–$12,700 annually. The drug targets patients who experience exacerbations despite traditional triple therapy (LABA, LAMA, ICS), addressing an unmet need in COPD treatment.
Verona Pharma plc (VRNA) Q2 2024 Earnings Call Transcript
Verona Pharma plc (NASDAQ:VRNA ) Q2 2024 Earnings Conference Call August 8, 2024 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Christopher Martin - Chief Commercial Officer Tara Rheault - Chief Development Officer Conference Call Participants Andrew Tsai - Jefferies Group LLC Thomas Shrader - BTIG, LLC Raghuram Selvaraju - H.C. Wainwright & Co. Edward Thomason - Van Lanschot Kempen Operator Welcome to Verona Pharma's Second Quarter 2024 Financial Results and Operating Highlights Conference Call.
